Best Drug Discovery Software - Page 7

Iktos

Iktos is a pioneering company specializing in artificial intelligence (AI) and robotics to revolutionize drug discovery. By integrating generative AI with automated synthesis and testing, Iktos accelerates the development of new treatments, aiming to improve patient care through fully autonomous laboratories. Their innovative approach shortens the drug discovery phase to under two years, significantly enhancing efficiency in pharmaceutical research and development. Key Features and Functionality: - Generative AI Platform (Makya): Makya is Iktos's generative AI software-as-a-service (SaaS) platform designed for de novo drug design. It creates diverse, novel, and medicinal chemistry-like molecules, ensuring each is synthetically accessible and optimized for success. - Retrosynthesis AI (Spaya): Spaya is an AI-driven retrosynthesis platform that identifies the most feasible synthetic routes, converting target compounds into commercially available starting materials. This data-driven approach optimizes the synthesis process, making it compatible with robotic systems. - Autonomous Laboratory (Iktos Robotics Chemistry): Iktos's autonomous lab manages the complete synthetic process, from workflow management and ordering raw materials to executing chemical synthesis. This AI-driven Design-Make-Test-Analyze (DMTA) process significantly reduces the time to identify viable drug candidates. - In-Cellulo Screening (Iktos Robotics Biology): Utilizing multidimensional biological data generated from their imaging platform, Iktos identifies small-molecule modulators of protein activity, protein-protein, and RNA-protein interactions in biologically relevant environments. This enables continuous optimization of molecular properties, even for challenging targets. Primary Value and Problem Solved: Iktos addresses the inefficiencies in traditional drug discovery by integrating AI and robotics, thereby accelerating the development of new therapeutics. Their platform enables rapid identification and optimization of drug candidates, reducing the time and cost associated with bringing new drugs to market. By automating the DMTA cycle and ensuring synthetic accessibility, Iktos enhances productivity in pharmaceutical R&D, ultimately contributing to improved patient outcomes.

Inference

Inference is the world's first agentic AI genomic discovery platform, developed by Variant Bio to revolutionize pharmaceutical research and development. By integrating proprietary and public genetic and multi-omic data with advanced AI capabilities, Inference enables R&D teams to uncover novel therapeutic targets and accelerate the development of life-saving treatments. Key Features and Functionality: - Agentic AI Capabilities: Inference Agents autonomously perform complex analyses, generating new insights from foundational data using first principles, rather than merely summarizing existing information. - Comprehensive Data Integration: The platform harmonizes data from major genetic and multi-omic association studies, including numerous global biobanks and proprietary datasets from underrepresented populations, creating the largest unified source of human genomic data for drug discovery. - Interactive Tools: Users can query live data across hundreds of millions of associations in seconds, run colocalization analyses on demand, and combine studies in real time, facilitating dynamic and iterative discovery processes. Primary Value and Problem Solved: Inference addresses the longstanding challenge in drug discovery of distinguishing correlation from causation. Traditional methods often identify associations without clarifying causal mechanisms, leading to inefficiencies and higher failure rates in clinical trials. By leveraging human genetics to reveal causal relationships, Inference enhances the likelihood of clinical success. Drugs with genetic support are 2.6 times more likely to succeed in clinical trials, and genetically validated targets have 50% lower odds of causing adverse effects. Inference empowers pharmaceutical companies to make informed decisions, prioritize programs with strong genetic validation, and ultimately bring effective treatments to patients more efficiently.

Insilico

We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development. Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.

Insilico Medicine (Pharma.AI)

InSilicoTrials

InSilicoTrials works with Pharma & Medical Devices companies to create a secure cloud-based computational hub in an easy & cheap way

Intrepid Labs

Intrepid Labs is a biotechnology research company founded in 2023, dedicated to accelerating the development of next-generation therapeutics by integrating active machine learning, advanced robotics, and deep pharmaceutical expertise. Their proprietary platform, VALIANT, is a modular, autonomous laboratory that leverages data-driven experiment planning to optimize drug formulations. By combining artificial intelligence and robotics, Intrepid Labs aims to transform active pharmaceutical ingredients into viable medicines more efficiently, significantly reducing the time and cost associated with traditional drug development methods.

Intrepid Labs

InVirtuoLabs

InVirtuoLabs is revolutionizing drug discovery by integrating advanced artificial intelligence with molecular simulations. Their proprietary platform combines machine learning techniques—such as multimodal learning, active learning, and generative chemistry—with physics-based simulations to efficiently explore vast chemical spaces. This synergy enables rapid identification and optimization of promising drug candidates, significantly accelerating the development of life-changing therapies. Key Features and Functionality: - InVirtuoMOL: A molecular machine learning engine that swiftly evaluates critical properties of potential drug candidates, reducing processing time by 90%. - InVirtuoGEN: A multimodal generative AI module capable of generating up to 1 billion novel molecules per day, expanding the exploration of chemical spaces. - InVirtuoSIM: A physics-based simulation workflow providing detailed insights into drug-target interactions at the atomic level, enhancing predictive models and reducing late-stage failures. Primary Value and Solutions: InVirtuoLabs addresses the challenges of traditional drug development by significantly reducing both the time and cost associated with bringing new drugs to market. Their platform has demonstrated the potential to double success rates compared to conventional methods, cutting development costs—currently exceeding €2.4 billion per drug—and shortening development timelines, which average 12 years. By leveraging AI and molecular simulations, InVirtuoLabs makes drug discovery faster, more precise, and economically sustainable, ultimately making innovative treatments more accessible to patients worldwide.

iStability LIMS

iStability LIMS is a turn-key Laboratory Information Management System (LIMS) tailored to pharmaceutical stability testing programs and stability management. It can be installed at your site and be up and running in less than a day.

iTraX

iTraX enables smarter R&D workflow management for pharma, biotech, and CROs. The cloud-based platform helps connect R&D teams and improves visibility, efficiencies and productivity within complex scientific workflows. iTraX is configurable and is built to integrate to other informatics tools in order to simplify operations and replace disconnected processes. Our solutions span across chemistry, analytical chemistry, preclinical study management and scheduling, as well as other R&D applications.

Kaleido

Kaleido is the first company to use a chemistry-driven approach to systematically drive functional outputs of the microbiome organ.

Kanteron

PRECISION MEDICINE AT THE POINT OF CARE

Kantify

LifeSphere

ArisGlobal’s LifeSphere platform is a suite of unified cloud solutions that helps hundreds of global life sciences companies accelerate development, maintain compliance and streamline collaboration between cross-functional teams. LifeSphere enables the life sciences industry to bring safer products to market more quickly.

LigPlot+

LigPlot+ is a successor to our original LIGPLOT program for automatic generation of 2D ligand-protein interaction diagrams. It is run from an intuitive java interface which allows on-screen editing of the plots via mouse click-and-drag operations.